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Abstract
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system with an important genetic
component and strongest association driven by the HLA genes. We performed a pooling-based genome-wide association
study of 500,000 SNPs in order to find new loci associated with the disease. After applying several criteria, 320 SNPs were
selected from the microarrays and individually genotyped in a first and independent Spanish Caucasian replication cohort.
The 8 most significant SNPs validated in this cohort were also genotyped in a second US Caucasian replication cohort for
confirmation. The most significant association was obtained for SNP rs3129934, which neighbors the HLA-DRB/DQA loci and
validates our pooling-based strategy. The second strongest association signal was found for SNP rs1327328, which resides in
an unannotated region of chromosome 13 but is in linkage disequilibrium with nearby functional elements that may play
important roles in disease susceptibility. This region of chromosome 13 has not been previously identified in MS linkage
genome screens and represents a novel risk locus for the disease.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system mediated by T-cell responses
to myelin antigens [1]. Epidemiological studies have demonstrated
that genetic factors contribute to the development of MS and
probably represent the most important etiological component,
although environmental factors likely contribute as well to disease
manifestation and phenotypic expression [2]. During the last two
decades, many investigative teams have devoted substantial efforts
to identifying the individual genes that confer susceptibility to MS,
and the following main conclusions have evolved from this work.
1/ MS is a complex genetic disease with multiple genes
contributing with probably modest effects to disease susceptibility.
2/ Among the suspected susceptibility genes, the HLA-class II
region on chromosomal area 6p21 contributes by far the most to
genetic susceptibility and has been confirmed in many genetic
studies in MS. In Caucasians, the ethnic group with the highest
prevalence of MS, it is particularly the HLA-class II genes, HLA-
DRB1*1501, -DRB5*0101, -DQA1*0102, -DQB1*0602, that are
associated with MS [3,4]. 3/ Genetic studies aiming to identify
additional genes that confer susceptibility to MS have been rather
disappointing, as many of the candidate genes identified in one
study were not confirmed in others. It has not been until recently
that two genes located outside the HLA region, the interleukin-2
receptor a (IL2RA) and the interleukin-7 receptor a (IL7RA), have
been proposed as strong candidates for MS susceptibility in several
studies [5–7]. Although the IL2RA and IL7RA genes exert much
weaker effects than the HLA-class II genes, associations of these
two genes with the disease have been confirmed in several
independent MS cohorts.
Identification of these genes occurred through the use of a
genome-wide association study of several hundred thousand single
nucleotide polymorphisms (SNPs) in a broadly selected Caucasian
population. Due to the need to multiple-test correct for the large
number of SNPs assayed, the false negative rate for associations is
quite high. An alternate approach is a two-stage design whereby
an associated gene is found in a narrow population by a genome-
wide screen and then evaluated in other populations. This
approach is most effective when the associated allele is enriched
in the initial population, such as due to a population bottleneck,
but still present in the outbred population. However, the large cost
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3490associated with individually genotyping hundreds of individuals is
often cost-prohibitive for the initial population. A more cost-
effective alternative to individually genotyping thousands of
samples on high-density SNP microarrays is the use of pooling-
based GWA studies [8]. Effectively, a pooling-based GWA study
accomplishes many of the objectives of individual genotyping and
specifically allows for identification of many of the SNPs with the
largest allelic frequency differences. In particular for MS, we can
validate the GWA study-design and pooling-based approach since
the HLA locus is clearly and consistently associated with MS [3,4].
In our case, the pooling-based approach is particularly attractive
since it allows us to test for associations across the Spanish
population at relatively low cost as compared to individual
genotyping, hypothesizing that additional genetic loci involved in
conferring risk of MS could be identified through pooling-based
GWA studies in this highly unique population.
Materials and Methods
Spanish Caucasian original cohort
A total of 242 unrelated patients with relapse-onset MS visited
at the outpatient clinic of the Unitat de Neuroimmunologia
Clı ´nica (UNIC) were included in the study. All subjects were of
Spanish origin and satisfied Poser’s criteria for clinically definite
MS [9]. The control population comprised of 242 unrelated
individuals recruited at the hospital transfusion centre, which
serves the geographic area from where the patients were enrolled.
The study was approved by the Ethics Committee of Vall
d’Hebron University Hospital and informed consent was obtained
from all participants involved in the study. A summary of
demographic and clinical characteristics of MS patients and
controls is shown in Table 1.
Sample pooling and high-density SNP genotyping of the
Spanish Caucasian original cohort
Prior to quantitation all DNA samples were checked for quality
using 2% agarose gel electrophoresis, and obviously degraded
samples were excluded from the pooling analysis. Individual
genomic DNA concentration of each subject was determined in
triplicate with the Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. These triplicate values were used to calculate a
median concentration for each individual DNA. Individual DNA
samples were then added to their respective pools in equivalent
molar amounts. Once created, each pool was diluted to 50 ng/ml
with sterile water in preparation for genotyping. Samples were
genotyped (or allelotyped) on 9 replicate Affymetrix 500 K EA
arrays, following the Affymetrix protocols (www.affymetrix.com).
Analysis of pooled data from the SNP arrays
Probe intensity data was directly read from CEL files and
Relative Allele Signal (RAS) values were calculated for each
quartet. RAS values correspond to the ratio of the A probe to the
sum of the A and B probes (where A is the major allele, and B is
the minor allele), and provide a quantitative index correlating to
allele frequencies in pooled DNA. These values yield independent
measures of different hybridization events and are consequently
treated as individual data points.
We used a silhouette statistic to rank all genotyped SNPs, since
there are six paired-probes per SNP. This particular test-statistics has
been heuristically shown to perform well at identifying SNPs with
large allelic frequency differences, without merging data from
fundamentally different probes even if for the same SNP.
Consequentially, this test-statistic was utilized as it avoids introducing
unnecessary variance by averaging probe intensity data from probes
with different hybridization properties. This silhouette statistic
intuitively represents the mean of the distance of a point to all other
points in its class versus points in the other class. Silhouette scores
range from 1, where significant separation between data points has
been achieved and cluster assignment can be made with confidence,
to 21, where differences in allelic frequencies are less reliable. The
calculation for a silhouette score is shown in equation (1):
S~
P
i~1::N
si ðÞ
N
, si ðÞ ~
bi ðÞ {ai ðÞ
max ai ðÞ ,bi ðÞ fg
g ð1Þ
Here, the overall silhouette score, S, is the average of all of the
individual silhouette values, s(i), for each of the measurements and
N refers to the number of replicate measures. Shown in
Equation 1, for a calculation of an s(i) value, b(i) refers to the
mean distance of a point to all points not within its class and a(i)
refers to the distance within its class. In this study, we have two
classes, MS cases and matched controls. SNPs were ranked based
on silhouette score, whereby the SNP with the highest score was
ranked 1 and the SNP with the lowest score was ranked 428,867
using Affymetrix’s Mendel3 libraries for the Affymetrix 500 K
arrays. With this ranking, it is assumed that SNPs approaching a
rank of 1 will have larger differences in allelic frequency.
Validation of candidate SNPs from the arrays by
individual genotyping in a first and independent Spanish
Caucasian replication cohort
We applied two criteria to select candidate SNPs for validation in
a replication cohort of cases and controls. A first criterion was to
Table 1. Demographic and clinical characteristics of the
Spanish MS patients and healthy controls involved in the
study.
Characteristics MS HC
Original Spanish cohort*
n 242 242
Female/male (% women) 161/81 (66.5%) 158/84 (65.3%)
Age (years)
a 43.5 (11.0) 43.9 (12.3)
RRMS/SPMS (% RRMS) 184/58 (76.0%) -
Spanish replication cohort**
n 100 100
Female/male (% women) 67/33 (67.0%) 65/35 (65.0%)
Age (years)
a 41.8 (10.3) 42.9 (12.6)
RRMS/SPMS (% RRMS) 80/20 (80.0%) -
US replication cohort**
n 275 275
Female/male (% women) 223/52 (81.0%) 220/55 (80.0%)
Age (years)
a 37.6 (8.9) 38.0 (9.5)
RRMS/SPMS (% RRMS) 275/0 (100.0%) -
*Refers to patients used for DNA pooling. **Refers to patients used for
individual validation.
aData are expressed as mean (standard deviation, SD).
RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive
multiple sclerosis; HC: healthy controls.
doi:10.1371/journal.pone.0003490.t001
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ranking SNPs using a silhouette statistic, as described above. A
secondcriterionwasto identifyclusters oftwoormore SNPslocated
in close proximity and scoring in the top 1%, and subsequently
select from each cluster the SNPs having the highest scores.
A Spanish Caucasian replication cohort comprised of one
hundred unrelated relapse-onset MS patients attended at the
outpatient clinic of the UNIC and one hundred controls from the
hospital transfusion centre was used for validation of the selected
top scoring SNPs. None of these MS patients and controls was part
of the original cohort used for DNA pooling. Demographic and
clinical characteristics of MS patients and controls are summarized
in Table 1. Statistical significance of individual genotype data was
calculated as an allelic x
2. This statistical model was chosen as it is
analogous to the type of allelic associations that would detectable
by a pooling-based GWA study.
DNAsamplesfrom this replicationcohortwerequantitated atthe
National Genotyping Center (CeGen, Madrid) using the PicoGreen
assay. An Illumina GoldenGate assay was utilized to individually
genotype SNPs selected from the Affymetrix 500 K platform.
Seven SNPs were discarded because of significant departures
from Hardy-Weinberg equilibrium. Two samples were also
discarded because their X chromosome genotypes were inconsis-
tent with their reported sex.
Quality control processes and allelic and genotypic association
tests were performed using the SNPator package (www.snpator.
com) [10].
US Caucasian replication cohort and SNP genotyping
A second replication cohort from the US and comprised of 275
unrelated relapse-onset MS patients and 275 controls was used to
confirm association of the most significant SNPs validated in the
Spanish replication cohort (those with p-values ,0.01 following
allelic frequency comparisons between cases and controls). A
description of the demographic and clinical characteristics of the
US replication cohort is shown in Table 1. DNA samples from this
replication cohort were quantitated at TGen using the PicoGreen
assay and individually genotyped for the selected SNPs by means
of the TaqMan allelic discrimination assay.
Results
A schematic flow chart summarizing the main steps of the study
design and analysis is represented in Figure S1. A ranked list of
428,867 SNPs was obtained from analysis of the probe intensity
differences between a pool of 242 Spanish relapse-onset MS
individuals genotyped on 9 Affymetrix 500 K EA arrays and a
pool of 242 Spanish healthy controls, also genotyped on 9
Affymetrix 500 K EA arrays. While a variety of analysis
approaches can be conceived for detecting statistically significant
differences in allelic frequency, we chose to implement an
approach previously demonstrated effective at identifying the
correct genetic loci in other pooling-based studies in complex
diseases [8]. In this approach, separation of relative allele signals
(RAS) between probe intensities for six unique probes between
cases and controls are calculated using a silhouette test-statistic.
This approach does not require that allele frequency be calculated
from a large number of individually genotyped samples and does
not assume that probes interrogate the same SNP with different 25
base oligos having the same hybridization properties. For the
Affymetrix 500 K platform, this is a particular advantage since a
SNP is probed by 6 to 10 probe pairs, each frequently with a
different sequence (referred to as offset probes, where the SNP is
not in the 13
th position). As expected, there has been evidence that
some probes may poorly discriminate and some probes may
preferentially bind one allele over another. The use of the
silhouette statistics avoids adding unnecessary noise resulting from
averaging fundamentally different measurements. The purpose of
this paper is not to compare or contrast different methods, but
rather to utilize a proven method to gain insight into the genetic
basis of MS.
From the ranked list of SNPs and after applying the two selection
criteria mentioned in Materials and Methods, a total of 320 SNPs
were chosen for individual genotyping in a first and independent
Spanish replication cohort of 100 MS cases and 100 healthy
controls,inordertovalidateresultsfromthepooledSNParrays.We
did not genotype in our original pooled cohorts since the purpose
was not to evaluate pooling (as has been done elsewhere) and since
thecost todo sowouldhaveincreased the overallcost ofthe studyto
a level where individual genotyping would be more cost effective.
Calculated association statistics are shown in Table 2 for the 8 SNPs
showing greatest significance (p,0.01 after allelic frequency
comparisons) and the full list is provided as Table S1. As expected
in replicated association studies, most SNPs do not show association
in the replication cohort.
Our GWA study design and the pooling-based strategy is
essentially validated by the fact that the single most significant SNP
neighbors the HLA-DRB/DQA loci. Specifically, rs3129934 is
approximately 200 kb from the HLA-DRB1 locus (Figure 1) and
has a p-value of 1.4610
25 with an OR of 3 (Table 2). Previous
studies have identified linkage disequilibrium between HLA
haplotypes and tagSNPs within the MHC [11]. Based on these
data, rs3129934 is in very high linkage disequilibrium with SNP
rs3135388 and demonstrated to tag the HLA-DRB associated
haplotype in MS (D9=0.964 R
2=0.93). The extremely strong
linkage disequilibrium between these two markers allows us to
conclude that the association of rs3129934 results from the HLA-
DRB1 locus and that the association observed with rs3129934
does not represent a second MHC association signal.
The SNP rs1327328 has the next greatest association, with a p-
value of 1.8610
23 and an OR of 1.9 (Table 2). This SNP resides
in a largely unannotated region of the genome. A second SNP
(rs7326018) in this region also shows a p-value of 0.0050.
Haplotype-based association analysis was completed using Haplo-
view 3.32 for the two SNPs. In this analysis, four common
haplotypes are observed, with significance being observed in the
H1 and H2 haplotypes (Table 3).
Finally, five additional SNPs that were found to be associated
with the disease in the Spanish replication cohort are the following
(Table 2): rs7141612, intronic SNP in the NPAS3 gene (neuronal
PAS domain-containing protein 3); rs7821848, SNP located
upstream of the SNTG1 gene (syntrophin, gamma 1);
rs10925318, intronic SNP in the RYR2 gene (ryanodine receptor
2); rs4902496, SNP located in the 3’untranslated region of the
PLEKHH1 gene (pleckstrin homology domain containing, family
H (with MyTH4 domain) member 1); rs7204129, intronic SNP in
the CDH13 gene (cadherin 13, H-cadherin (heart)).
Additional genotyping was conducted for those SNPs having
highest significance in a new separate US Caucasian population
consisting of up to 275 MS cases and 275 controls. The association
statistics for these SNPs are shown in Table 4. The single most
significant SNP, as expected, was rs3129934 neighboring the
HLA-DRB1 locus with an allele-based p-value of 4.2610
210. The
second most significant SNP was rs1327328 on chromosome 13
with an allele based p-value of 0.0030, replicating the previously
mentioned p-value of 1.8610
23. For rs1327328, the association is
driven by an excess of the T allele in both MS relapse-onset
populations. The neighboring rs7326018 also showed significance
Novel Risk Locus for MS
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SNP Location Analysis MS, N (%) HC, N (%) OR (95% CI) P value
rs3129934 Chr. 6 Allele n=198 n=186
C 133 (67.2%) 160 (86.0%)
T 65 (32.8%) 26 (14.0%) 3.0 (1.8–5.0) 1.4610
25
Genotype n=99 n=93
CC 50 (50.5%) 69 (74.2%)
CT 33 (33.3%) 22 (23.7%)
TT 16 (16.2%) 2 (2.2%) 2.8 (1.5–5.2) 0.0007
rs1327328 Chr. 13 Allele n=198 n=188
C 70 (35.4%) 96 (51.1%)
T 128 (64.6%) 92 (48.9%) 1.9 (1.3–2.9) 0.0018
Genotype n=99 n=94
CC 12 (12.1%) 29 (30.9%)
CT 46 (46.5%) 38 (40.4%)
TT 41 (41.0%) 27 (28.7%) 3.2 (1.5–6.8) 0.0015
rs7141612 Chr. 14 Allele n=198 n=188
C 145 (73.2%) 112 (59.6%)
T 53 (26.8%) 76 (40.4%) 1.9 (1.2–2.9) 0.0045
Genotype n=99 n=94
CC 53 (53.5%) 35 (37.2%)
CT 39 (39.4%) 42 (44.7%)
TT 7 (7.1%) 17 (18.1%) 2.9 (1.1–7.4) 0.0205
rs7821848 Chr. 8 Allele n=198 n=186
C 178 (89.9%) 148 (79.6%)
G 20 (10.1%) 38 (20.4%) 2.3 (1.3–4.1) 0.0047
Genotype n=99 n=93
CC 80 (80.8%) 58 (62.4%)
CG 18 (18.2%) 32 (34.4%)
GG 1 (1.0%) 3 (3.2%) 2.5 (1.3–4.9) 0.0045
rs10925318 Chr. 1 Allele n=198 n=188
C 104 (52.5%) 72 (38.3%)
T 94 (47.5%) 116 (61.7%) 1.8 (1.2–2.7) 0.0050
Genotype n=99 n=94
CC 29 (29.3%) 17 (18.1%)
CT 46 (46.5%) 38 (40.4%)
TT 24 (24.2%) 39 (41.5%) 2.2 (1.2–4.1) 0.0106
rs7326018 Chr. 13 Allele n=198 n=188
A 129 (65.2%) 96 (51.1%)
T 69 (34.8%) 92 (48.9%) 1.8 (1.2–2.9) 0.0050
Genotype n=99 n=94
AA 43 (43.4%) 28 (29.8%)
AT 43 (43.4%) 40 (42.6%)
TT 13 (13.1%) 26 (27.7%) 2.5 (1.2–5.3) 0.0120
rs4902496 Chr. 14 Allele n=198 n=188
C 39 (19.7%) 18 (9.6%)
G 159 (80.3%) 170 (90.4%) 2.3 (1.3–4.2) 0.0051
Genotype n=99 n=94
CC 2 (2.0%) 2 (2.1%)
CG 35 (35.4%) 14 (14.9%)
GG 62 (62.6%) 78 (83.0%) 3.1 (1.6–6.3) 0.0011
rs7204129 Chr. 16 Allele n=198 n=188
Novel Risk Locus for MS
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rium with rs1327328 (D9=0.95, R
2=0.91). Just as before,
haplotype analysis revealed association of the H1 and H2
haplotypes with the disease (p=0.03 and 0.01 respectively; see
Table 3). The H3 haplotype also shows association at p=0.006,
though some caution must be used with interpretation due to the
low frequency (2.1%) of this haplotype compared to the H1, H2,
and H4 haplotypes. Beyond these three SNPs, no other of the 8
genotyped SNPs showed association in the new US replication
cohort (Table 4).
SNP rs1327328 was genotyped in an additional US Caucasian
population of 178 MS cases (mean age (standard deviation): 37.0
(9.9); % women: 81%; % relapsing-remitting MS: 100%) and 658
controls (mean age: 38.0 (11.9); % women: 80% female). Table 5
depicts allele and genotype associations obtained for the combined
Caucasian replications cohorts comprised of up to 553 MS cases
and 1033 controls. Both allele T (OR=1.3; 95% CI=1.1 to 1.5;
p=5.0610
24) and TT homozygosity (OR=1.4; 95% CI=1.1 to
1.8; p=1.7610
23) for SNP rs1327328 were associated with
relapse-onset MS. Individual association analysis obtained for the
whole US replication cohort is also shown in Table 5.
As mentioned above, SNPs rs1327328 and rs7326018 lie in a
position of chromosome 13 devoid of any known functional
elements. As shown in Figure 2, the region were these SNPs are
located contains several genes (ENSG00000184837,
ENSG00000165618 and LOC121727) and microRNAs (hsa-mir-
622, hsa-mir-17, hsa-mir-18a, hsa-mir-19a, hsa-mir-20a and hsa-mir-
19b-1). Within or close to some of these functional elements, there
Figure 1. Graphs showing physical position of SNP rs3129934 on chromosome 6. SNP rs3129934, which showed the strongest association
with the disease in the Spanish and US replication cohorts, is located approximately 200 kb from the HLA-DRB1 locus.
doi:10.1371/journal.pone.0003490.g001
Table 3. Haplotype analysis from SNPs rs7326018 and
rs1237238 in the Spanish and US replication cohorts.
Haplotypes Total, N MS, N (%) HC, N (%) OR (95% CI) P value
Spanish replication cohort
(H1) AT 217 126 (63.6) 91 (48.4) 1.9 (1.2–2.8) 0.0026
(H2) TC 158 67 (33.8) 91 (48.4) 0.5 (0.4–0.8) 0.0036
(H3) AC 8 3 (1.5) 5 (2.7) 0.6 (0.1–2.4) 0.4302
(H4) TT 3 2 (1.0) 1 (0.5) 1.9 (0.2–21.2) 0.5928
US replication cohort
(H1) AT 293 164 (61.9) 129 (54.4) 1.4 (1.0–1.7) 0.0293
(H2) TC 192 92 (34.7) 100 (42.2) 0.7 (0.4–1.0) 0.0116
(H3) AC 14 7 (2.6) 7 (3.0%) 0.9 (0.1–1.8) 0.0058
(H4) TT 3 2 (0.8) 1 (0.4%) 1.8 (0.1–3.6) 0.1701
First haplotype position refers to SNP rs7326018 and second position to SNP
rs1237238. OR: odds ratio; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0003490.t003
SNP Location Analysis MS, N (%) HC, N (%) OR (95% CI) P value
C 149 (75.3%) 117 (62.2%)
G 49 (24.7%) 71 (37.8%) 1.8 (1.2–2.9) 0.0057
Genotype n=99 n=94
CC 54 (54.5%) 34 (36.2%)
CG 41 (41.4%) 49 (52.1%)
GG 4 (4.0%) 11 (11.7%) 2.1 (1.2–3.8) 0.0104
Bold alleles denote risk alleles. Only the most statistically significant genotype comparisons are represented: rs3129934: CT+TT vs CC; rs1327328: CT+TT vs CC;
rs7141612: CC+CT vs TT; rs7821848: CC vs CG+GG; rs10925318: CC+CT vs TT; rs732618: AA+AT vs TT; rs4902496: CG vs CC+GG; rs7204129: CC vs CG+GG.
doi:10.1371/journal.pone.0003490.t002
Table 2. cont.
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SNP Location Analysis MS, N (%) HC, N (%) OR (95% CI) P value
rs3129934 Chr. 6 Allele n=550 n=480
C 376 (68.4%) 408 (85.0%)
T 174 (31.6%) 72 (15.0%) 2.6 (1.9–3.6) 4.2610
210
Genotype n=275 n=240
CC 124 (45.1%) 176 (73.3%)
CT 128 (46.5%) 56 (23.3%)
TT 23 (8.4%) 8 (3.3%) 3.3 (2.3–4.9) 9.0610
211
rs1327328 Chr. 13 Allele n=548 n=482
C 197 (35.9%) 217 (45.0%)
T 351 (64.1%) 265 (55.0%) 1.4 (1.1–1.9) 0.0030
Genotype n=274 n=241
CC 37 (13.5%) 47 (19.5%)
CT 123 (44.9%) 123 (51.0%)
TT 114 (41.6%) 71 (29.5%) 1.7 (1.2–2.5) 0.0042
rs7141612 Chr. 14 Allele n=544 n=478
C 363 (66.7%) 300 (62.8%)
T 181 (33.3%) 178 (37.2%) 1.2 (0.9–1.5) 0.1851
Genotype n=272 n=239
CC 128 (47.1%) 99 (41.4%)
CT 107 (39.3%) 102 (42.7%)
TT 37 (13.9%) 38 (15.9%) 1.3 (0.9–1.8) 0.2008
rs7821848 Chr. 8 Allele n=552 n=484
C 451 (81.7%) 389 (80.4%)
G 101 (18.3%) 95 (19.6%) 1.1 (0.8–1.5) 0.5852
Genotype n=276 n=242
CC 186 (67.4%) 159 (65.7%)
CG 79 (28.6%) 71 (29.3%)
GG 11 (4.0%) 12 (5.0%) 1.3 (0.5–2.9) 0.5916
rs10925318 Chr. 1 Allele n=556 n=486
C 296 (53.2%) 247 (50.8%)
T 260 (46.8%) 239 (49.2%) 1.1 (0.9–1.4) 0.4364
Genotype n=278 n=243
CC 77 (27.7%) 59 (24.3%)
CT 142 (51.1%) 129 (53.1%)
TT 59 (21.2%) 55 (22.6%) 1.2 (0.8–1.8) 0.3755
rs7326018 Chr. 13 Allele n=536 n=478
A 338 (63.1%) 273 (57.1%)
T 198 (36.9%) 205 (42.9%) 1.3 (1.0–1.6) 0.0534
Genotype n=268 n=239
AA 102 (38.1%) 80 (33.5%)
AT 134 (50.0%) 113 (47.3%)
TT 32 (11.9%) 46 (19.2%) 1.8 (1.1–2.9) 0.0228
rs4902496 Chr. 14 Allele n=540 n=486
C 99 (18.3%) 105 (21.6%)
G 441 (81.7%) 381 (78.4%) 1.2 (0.9–1.7) 0.1899
Genotype n=270 n=243
CC 11 (4.1%) 10 (4.1%)
CG 77 (28.5%) 85 (35.0%)
GG 182 (67.4%) 148 (60.9%) 1.3 (0.9–2.0) 0.1160
rs7204129 Chr. 16 Allele n=198 n=188
Novel Risk Locus for MS
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rium analysis between SNPs rs1327328 and rs7326018 and the
SNPs mapping in the functional elements is summarized in
Table 6. Linkage disequilibrium measures are highly significant
between SNPs rs1327328 and rs7326018 and SNP rs4284505,
located next to a cluster of microRNAs, and marginally significant
with SNP rs9583760, located within LOC121727 (similar to
Peroxisome assembly protein 12 (Peroxin-12) (Peroxisome assem-
bly factor 3) (PAF-3)).
Discussion
Despite a large number of studies on susceptibility genes for MS,
these efforts during the last two decades have been notably
disappointing. Several whole genome screens and many linkage
and association studies have only shown one genetic region with
high consistency, the HLA-class II region on 6p21 and in
Caucasian MS patients [3,4]. Recently, two cytokine receptors,
IL7RA and IL2RA, have been shown to contribute to the non-
HLA-related susceptibility to MS [5–7]. Nevertheless, MS is a
complex trait disease and additional loci are expected to be
contributing to the genetic risk in MS.
In the present study we used a recently developed and validated
DNA pooling strategy and SNP array genotyping of 9 replicate
pools as a first step. As the main advantage, this approach allows
cutting costs and hence permitted us to perform the study on a
novel population in order to screen a large number of SNPs for
allelic association. Due to the large number of SNPs some
correction is necessary in order to account for multiple testing. We
did not genotype our original population, and all p-values are
obtained from new cohorts that are completely non-redundant
with the original pooled populations. Under the most conservative
of scenarios, the p-values reported in Table 2 must survive a
Bonferroni-corrected significance level of p=1.5610
24. This is an
overly conservative number since some SNPs do show linkage
disequilibrium between each other and, thus, the assumption of
test independence central to the Bonferroni correction is not met.
Still, rs3129934 survives this Bonferroni corrected significance
level and, likewise, is known to be in strong linkage disequilibrium
with markers in the HLA-DRB1 locus [11]. As fully expected,
rs3129934 showed also the highest association in the US
Caucasian replication cohort. These findings validate the pool-
ing-based strategy that has been used in our study. Several studies
have shown that MS is primarily associated with the DR2
haplotype (DRB1*1501-DQB1*0602) in the Spanish population.
In addition, our results are in agreement with previous
publications suggesting that the effect of HLA is less significant
in the Spanish population compared with other US populations
with higher disease incidence [12,13].
SNP rs1327328 showed the second strongest association with
MS in the Spanish replication cohort with a p-value of 1.8610
23.
A second SNP, rs7326018, located approximately 30 kb from
rs1327328 and in strong linkage disequilibrium with the latter was
also associated with the disease in this replication cohort. The fact
that both rs1327328 and rs7326018 show strong evidence for
association suggests that genotyping error is not leading to a false
association. SNP rs1327328 was validated in the US Caucasian
population, with an allele-based p-value of 0.003, below the 0.006
Bonferroni-corrected significance threshold.
SNPs rs1327328 and rs7326018 are located in the long arm of
chromosome 13, at 13q31.3, in a region that has not been
previously identified in MS linkage genome screens. In addition,
rs1327328 and rs7326018 have not been found associated with the
disease in other GWA studies. Thus, this region represents a novel
risk locus for the disease. As mentioned before, this region of
chromosome 13 is largely unannotated with no functional
Table 5. Association analysis of SNP rs1327328 in the
combined Spanish and US replication cohorts.
Analysis MS, N (%) HC, N(%) OR (95% CI) P value
Combined* Allele n=1106 n=2066
C 426 (38.5) 927 (44.9)
T 680 (61.5) 1139 (55.1) 1.3 (1.1–1.5) 5.0610
24
Genotype n=553 n=1033
CC 85 (15.4) 208 (20.1)
CT 256 (46.3) 511 (49.5)
TT 212 (38.3) 314 (30.4) 1.4 (1.1–1.8) 1.7610
23
US cohort** Allele n=908 n=1878
C 356 (39.2) 831 (44.2)
T 552 (60.8) 1047 (55.8) 1.2 (1.0–1.4) 0.0116
Genotype n=454 n=939
CC 73 (16.1) 179 (19.1)
CT 210 (46.3) 473 (50.4)
TT 171 (37.7) 287 (30.6) 1.4 (1.1–1.7) 0.0082
*Meta-analysis for pooled cohorts (Spanish and US) was performed using the
Mantel-Haenszel test implemented in SAS 9.0. **Refers to the individual results
obtained for the whole US replication cohort. Risk alleles are shown in bold.
Only the most statistically significant genotype comparisons are represented
(TT vs CC+CT in both analyses). OR: odds ratio; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0003490.t005
SNP Location Analysis MS, N (%) HC, N (%) OR (95% CI) P value
C 356 (65.4%) 306 (63.5%)
G 188 (34.6%) 176 (36.5%) 1.1 (0.8–1.4) 0.5135
Genotype n=272 n=241
CC 109 (40.1%) 97 (40.2%)
CG 138 (50.7%) 112 (46.5%)
GG 25 (9.2%) 32 (13.3%) 1.5 (0.9–2.6) 0.1416
Bold alleles denote risk alleles. Genotype comparisons: rs3129934: TT+CT vs CC; rs1327328: TT vs CT+CC; rs7141612: CC vs CT+TT; rs7821848: CC+CG vs GG; rs10925318:
CC vs CT+TT; rs732618: AA+AT vs TT; rs4902496: CC+GG vs CG; rs7204129: CC+CG vs GG.
doi:10.1371/journal.pone.0003490.t004
Table 4. cont.
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associations detected for these SNPs, a possibility is that they are
acting as markers of some nearby elements. Interestingly,
rs1327328 and rs7326018 are in high linkage disequilibrium with
other SNPs mapping within or close to a cluster of microRNAs.
MicroRNAs are a class of small regulatory RNAs that regulate
gene expression [14], and polymorphisms located within or in
proximity to microRNAs may contribute to disease susceptibility
[15]. Several members of this microRNA cluster found to be in
linkage disequilibrium with the MS-associated SNPs rs1327328
and rs7326018 are known to negatively regulate the expression of
the transcription factor E2F1 [16]. The E2F transcription factor
family, with E2F1 as the best characterized member, plays a
crucial role in the control of cell cycle [17]. Of note, the E2F
pathway has been implicated in autoimmunity [18], and a gene
expression profiling study with microarrays found an overrepre-
sentation of the E2F pathway in PBMC from relapse-onset MS
patients when compared with healthy controls [19].
Linkage disequilibrium is also significant between SNPs
rs1327328 and rs7326018 and markers mapping within or close
to locus LOC121727. This locus is a possible gene with homology
to the peroxisomal biogenesis factor 12 (PEX12). Of note,
mutations in human PEX12 result in Zellweger syndrome
[20,21], one of a group of several related diseases called
peroxisome biogenesis disorders, which are part of a larger group
of diseases known as the leukodystrophies [22]. These findings
suggest that nearby elements in linkage disequilibrium with SNPs
rs1327328 and rs7326018 may be playing important roles in MS
susceptibility.
Finally, 5 of the 8 SNPs that were validated in the Spanish
replication cohort were not associated with the disease in the US
population. Regarding the ethnic background of the MS patients
that were part of the replication cohorts, they are all Caucasian,
however, one probably has to consider different ethnic admixtures
in the US Caucasian and the Spanish Caucasian MS cohorts.
Additionally, there are regional differences between MS preva-
lence and it is possible that susceptibility alleles for MS in a
Spanish MS population may not be prevalent in a US Caucasian
population. Consequentially, failure to see association of the other
SNPs does not provide definitive evidence of a negative
association, and these SNPs may represent regions of potential
susceptibility to MS in the Spanish population. Furthermore, none
of the 8 SNPs validated in the Spanish replication cohort by
individual genotyping were found associated with the disease in a
recent genomewide study conducted by the International Multiple
Sclerosis Genetics Consortium [7].
In summary, by using a pooling-based approach and high
density SNP arrays we confirmed the well-known association of
the HLA class II genes with the disease, and identified a novel risk
locus for MS on chromosome 13. Nevertheless, these findings are
of preliminary nature and future studies will be needed to validate
these results on chromosome 13 and to further implicate the
functional elements of this region in disease susceptibility.
Figure 2. Graph illustrating genes located in proximity to SNPs rs1327328 and rs7326018 on chromosome 13. SNP rs1327328 was the
second most significant SNP validated in the Spanish and US replication cohorts, and is in strong linkage disequilibrium with SNP rs7326018. SNPs
rs1330943, rs9588771, rs6492466, rs9583760, rs4284505, and rs9589207 have been typed by HapMap.
doi:10.1371/journal.pone.0003490.g002
Table 6. Linkage disequilibrium analysis between SNPs
rs7326018 and rs1327328 and neighboring SNPs in
chromosome 13.
SNP pairs D9 r
2 Chi
2 P value
rs7326018 rs1330943 0.3836 0.0023 0.4106 0.5217
rs1327328 0.9539 0.9099 163.7904 1.89610
215
rs9588771 0.0000 - 0 1
rs6492466 0.0563 0.0014 0.2467 0.6194
rs9583760 0.2725 0.0282 5.0707 0.0243
rs4284505 0.5002 0.1192 21.4486 3.63610
26
rs9589207 1.0000 0.0165 2.9644 0.0851
rs1327328 rs1330943 0.3836 0.0023 0.4106 0.5217
rs9588771 0.0000 - 0 1
rs6492466 0.0563 0.0014 0.2467 0.6194
rs9583760 0.2725 0.0282 5.0707 0.0243
rs4284505 0.5668 0.153 27.5447 1.54610
27
rs9589207 1.0000 0.0165 2.9644 0.0851
SNPs rs1330943 and rs9588771 are located in ENSG00000165618 and
ENSG00000184837 genes respectively; rs6492466 and rs9583760 are located
within LOC121727; rs4284505 is located close to a cluster of microRNAs and
rs9589207 within the hsa-mir-92a-1 microRNA. Linkage disequilibrium measures
are highly significant between SNPs rs1327328 and rs7326018 and SNP
rs4284505, and marginally significant with SNP rs9583760 (p values are
represented in bold).
doi:10.1371/journal.pone.0003490.t006
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Figure S1 Flow chart summarizing the different steps undertak-
en in the analysis of the study data. A ranked list of SNPs was
obtained from the analysis of the SNP arrays performed on pooled
DNA from 242 Spanish MS cases and 242 Spanish controls
(original Spanish cohort). After applying two criteria (arrows), 320
SNPs were selected for individual genotyping in an independent
Spanish cohort of 100 MS cases and 100 controls (Spanish
replication cohort (1)). The SNPs showing greatest significance
(p,0.01 after allelic frequency comparisons) were genotyped in a
US cohort comprised of 275 MS cases and 275 controls (US
replication cohort (2)). Two out of 8 SNPs (rs3129934 and
rs1327328) were validated in the US cohort. A third SNP
(rs7326018) showed marginal association in the US cohort. SNP
rs3129934 is located in close proximity to the HLA-DRB1 locus.
SNP rs1327328 was genoptyped in an additional US cohort of 178
MS cases and 658 controls and is located in chromosome 13, in a
region that represents a novel risk locus for MS.
Found at: doi:10.1371/journal.pone.0003490.s001 (0.69 MB TIF)
Table S1 Association analysis of the remaining 312 SNPs
selected from the pooled SNP arrays and genotyped in the Spanish
replication cohort.
Found at: doi:10.1371/journal.pone.0003490.s002 (0.46 MB
DOC)
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